Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02827877 · ClinicalTrials.gov registry record · Phase 2

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

A Phase 2 study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
18
Enrollment target
1
Study location

NCT02827877 is a Phase 2 study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 18 participants, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02827877, a Phase 2 study of Stage IIIA Breast Cancer and Stage IIIB Breast Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as copper Cu 64 DOTA-trastuzumab PET, may help predict a patient's response to trastuzumab and pertuzumab before surgery in patients with locally advanced HER2 positive breast cancer.

Conditions Studied

Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer HER2-Positive Breast Carcinoma

Interventions

  • PROCEDURE Positron Emission Tomography
  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Therapeutic Conventional Surgery
  • BIOLOGICAL Pertuzumab
  • RADIATION Copper Cu 64-DOTA-Trastuzumab

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2016-07-15
Est. Completion 2026-09-25
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02827877

The ClinicalTrials.gov registry entry for NCT02827877 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 281-participant average among 29 other Stage IIIA Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stage IIIA Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Positron Emission Tomography is the first listed.

NCT02827877 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02827877 about?

NCT02827877 is a clinical study titled "Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer". This phase II trial studies how well copper Cu64-DOTA-trastuzumab positron emission tomography (PET) works in predicting response to treatment with trastuzumab and pertuzumab before surgery in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread from w...

What is the current status of trial NCT02827877?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-07-15. Estimated completion is 2026-09-25.

What conditions does trial NCT02827877 study?

This clinical trial studies the following conditions: Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, HER2-Positive Breast Carcinoma.

What interventions are being tested in trial NCT02827877?

The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE), Pertuzumab (BIOLOGICAL), Copper Cu 64-DOTA-Trastuzumab (RADIATION).

Who is sponsoring clinical trial NCT02827877?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02827877 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IIIA Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IIIA Breast Cancer

All registered trials for this condition

Stage IIIB Breast Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.